Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0074 • ACR Convergence 2024
Tofacitinib Therapy Ameliorates Inflammation in a Mouse Model of Psoriasis and Arthritis by Inducing Type 2 Immunity
Maria de la Luz Garcia-Hernandez¹, Javier Rangel-Moreno¹, Ananta Paine², Angel Rangel-Garcia¹, Marissa Krantz³, Delaney Martino¹, Marc Nuzzo¹ and Christopher Ritchlin⁴, ¹University of Rochester, Rochester, NY, ²ORNA Tx, Southborough, MA, ³University of Rochester, Rochester, NY, ⁴Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Psoriatic arthritis (PsA), a chronic progressive inflammatory arthritis, affects peripheral joints and causes patient disability. PsA patients also have skin plaques initiated by activation…
Abstract Number: 0384 • ACR Convergence 2024
Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study
Corey J. Bishop¹, Edwin Lam², Sophia G. Liva³, Jocelyn H. Leu², Amy S. Paller⁴, Lucia Z. Diaz⁵, Laura Wine Lee⁶, Cory Rubin⁷, Ruy Carrasco⁸, Lisa Imundo⁹, Azadeh Majlessi¹⁰, Katherine Berezny¹, Kathleen G. Lomax¹, Valerie Smith¹, Renping Zhang¹ and hermine brunner¹¹, ¹Janssen Research & Development, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ⁴Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁵Dell Children’s Medical Center; Dell Medical School at the University of Texas at Austin, Austin, TX, ⁶Medical University of South Carolina, Charleston, SC, ⁷Michigan Dermatology Institute, Waterford, MI, ⁸Pediatric Rheumatology Consultants of Austin, Austin, TX, ⁹Columbia University Medical Center, New York, NY, ¹⁰Newport Huntington Medical Group, Huntington Beach, CA, ¹¹Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: Ustekinumab (UST), an interleukin‑12/23p40 antagonist, is currently approved for juvenile psoriatic arthritis (jPsA) solely in the United States (US). Although a phase 3 study…
Abstract Number: 0593 • ACR Convergence 2024
Value of the Routine Assessment of Patient Index Data 3 in Assessing Disease Severity and Treatment Effect in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast
Alvin F. Wells¹, Arthur Kavanaugh², William Tillett³, Philip S. Helliwell⁴, Marijn Vis⁵, Yuri Klyachkin⁶, Cynthia Deignan⁷, Lichen Teng⁷, Rebecca Wang⁷ and Alexis Ogdie⁸, ¹Rheumatology and Immunotherapy Center, Franklin, WI, ²University of California San Diego, La Jolla, CA, ³Royal National Hospital of Rheumatic Diseases; Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵Erasmus MC, Rotterdam, Netherlands, ⁶Amgen, Lexington, KY, ⁷Amgen Inc., Thousand Oaks, CA, ⁸Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) score is a composite of 3 patient-reported outcomes (PROs): Health Assessment Questionnaire (HAQ), pain visual…
Abstract Number: 1019 • ACR Convergence 2024
The Impact of Race and Ethnicity and Historical Redlining on Psoriatic Disease Burden
Brittany Banbury¹, Sharon Dowell², Christopher Jenkins³, Emily Holladay⁴, Fenglong Xie⁵, Jingyi Zhang⁵, Grace Wright⁶, Jeffrey Curtis⁷ and Gail Kerr⁸, ¹Mount Sinai Beth Israel, Brooklyn, NY, ²NEA Baptist Memorial Hospital, JONESBORO, AR, ³Medstar Georgetown University Hospital, Washington, DC, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Grace C Wright MD PC, New York, NY, ⁷University of Alabama at Birmingham, Hoover, AL, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Previous literature has suggested racial and ethnic variations in the clinical expression of psoriatic disease, with Non-White patients having more extensive skin disease, higher…
Abstract Number: 1436 • ACR Convergence 2024
The Association of Cigarette Smoking with Radiographic Progression in Psoriatic Arthritis
Fadi Kharouf¹, Hernan Maldonado Ficco², Shangyi Gao³, barry J Sheanne⁴, Daniel Pereira⁵, Richard Cook⁶, Vinod Chandran⁷ and Dafna Gladman⁸, ¹University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ²Hospital San Antonio de Padua, Cordoba, Argentina, ³Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴St James' Hospital, Dublin, Ireland, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Waterloo, Waterloo, Canada, ⁷University of Toronto, Toronto, ON, Canada, ⁸University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The association between smoking and radiographic damage has been established in axial spondyloarthritis and rheumatoid arthritis, but not in psoriatic arthritis (PsA). We designed…
Abstract Number: 1472 • ACR Convergence 2024
Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies
Philip Mease¹, Alice Gottlieb², Iain McInnes³, Natalie J. Shiff⁴, Anthony Todd⁵, Emmanouil Rampakakis⁶, Francois Nantel⁷, Jenna Parrett⁵, Frederic Lavie⁸ and Proton Rahman⁹, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ³University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, ⁴Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, ⁵Janssen Scientific Affairs, LLC, Horsham, PA, ⁶McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁷Nantel Medsci Consult, Montreal, QC, Canada, ⁸Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁹Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada
Background/Purpose: Guselkumab (GUS), a fully human IL-23p19-subunit inhibitor, has demonstrated multidomain efficacy (swollen/tender joints, psoriasis, enthesitis and dactylitis) in patients (pts) with active PsA in…
Abstract Number: 1935 • ACR Convergence 2024
Timely Referral of Patients with Inflammatory Rheumatic Diseases to Rheumatology: Validation of a Referral Algorithm with Frontline Physicians
Nelly Ziade¹, Karen Mechleb², Nizar Ani³, avin maroof⁴, ASAL ADNAN RIDHA⁵, Manal El Rakawi⁶, Chafika Haouichat⁶, Bassel Elzorkany⁷, Sherif Gamal⁸, Mariama Erraoui⁹, Manal Al-Mashaleh¹⁰, Fatima Alnaimat¹¹, Basel masri¹², fatemah Baron¹³, Lina El Kibbi¹⁴, Krystel Aouad¹⁵ and Ihsane Hmamouchi¹⁶, and ARCH - ArLAR, ¹Saint-Joseph University, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³Baghdad College of Medicine, Baghdad, Iraq, ⁴University of Kurdistan Hawler, Erbil, Iraq, ⁵Baghdad Teaching Hospital, baghdad, Iraq, ⁶Djillali Bounaama University Hospital, Algiers, Algeria, ⁷Private (BZRC), Cairo, Egypt, ⁸Cairo University, Cairo, Egypt, ⁹Souss Massa Univeristy, Rabat, Morocco, ¹⁰Royal Medical Services, Amman, Jordan, ¹¹University of Jordan, Amman, Jordan, ¹²Jordan Hospital and Medical Center, Amman, Jordan, ¹³Al-Jahra Hospital, Ministry of Health, Kuwait, Kuwait, ¹⁴Specialized Medical Center, Riyadh, Saudi Arabia, ¹⁵Saint George Hospital University Medical Center, Beirut, Lebanon, ¹⁶Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco
Background/Purpose: Early referral of patients with chronic inflammatory rheumatic diseases (CIRDs) to rheumatology is essential to reduce diagnostic delays and improve long-term prognosis. Referral strategies…
Abstract Number: 2319 • ACR Convergence 2024
Investigating the Association of Serum Metabolites with Psoriatic Arthritis Musculoskeletal Disease Patterns
Sheng Han Li¹, Nikita Looby², Max Kotiyar³, Lihi Eder⁴, Igor Jurisica⁵, Vathany Kulasingam⁶ and vinod Chandran⁷, ¹Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada, ²Psoriatic Arthritis Program Schroeder Arthritis Institute, Toronto, Canada, ³Data Science Discovery Centre for Chronic Dsiease, Krembil Research Institute, Toronto, Canada, ⁴University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, ⁵Data Science Discovery Centre, Krembil Research Institute, Toronto, Canada, ⁶Laboratory Medicine Program, Unviersity Health Network, Toronto, Canada, ⁷Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Accurate assessment of disease patterns may be important for appropriate management of psoriatic arthritis (PsA). Ultrasonography (USG) is a highly accurate, sensitive, and non-invasive…
Abstract Number: 2336 • ACR Convergence 2024
Patients with Psoriasis with a Positive Psoriasis Epidemiology Screening Tool (PEST): Similarities and Differences Compared to PsA and Patients with Psoriasis and a Negative PEST
Alexis Ogdie¹, William Song², Joel Gelfand², Sarah Lonowski³, Rebecca Schumacher⁴ and Kaleb Michaud³, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Forward Databank, Witchita, KS
Background/Purpose: Identifying patients at risk for developing psoriatic arthritis (PsA) may allow for accelerated diagnosis and treatment and improve long term outcomes for these patients.…
Abstract Number: 2357 • ACR Convergence 2024
Longitudinal Evaluation of Neutrophil-to-Lymphocyte Ratio in Guselkumab-Treated Patients with Psoriatic Disease and Levels of Systemic Inflammation Associated with Elevated Cardiovascular Risk: Post-hoc Analysis of 4 Phase 3, Randomized, Controlled Studies
Joseph Merola¹, Alexis Ogdie², Arthur Kavanaugh³, Evan Leibowitz⁴, Emmanouil Rampakakis⁵, Ryan Funk⁶, Francois Nantel⁷, Frederic Lavie⁸, Katelyn Rowland⁹ and Enrique R. Soriano¹⁰, ¹UT Southwestern Medical Center, Newton, MA, ²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of California San Diego, La Jolla, CA, ⁴Janssen Scientific Affairs, LLC, Fair Lawn, NJ, ⁵McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, ⁶Johnson & Johnson Innovative Medicine, Long Grove, IL, ⁷Nantel MedSci Consult, Montreal, QC, Canada, ⁸Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, ⁹Janssen Pharmaceuticals, Horsham, PA, ¹⁰Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: Psoriatic disease (PsD) is associated with an increased risk of cardiovascular (CV) disease. Neutrophil-to-lymphocyte ratio (NLR) is a biomarker of systemic inflammation; NLR ≥2.5…
Abstract Number: 2638 • ACR Convergence 2024
Defining Sonographic Enthesitis in Psoriatic Arthritis: Developing a Data- and Expert-driven Diagnostic Criteria for Inflammatory Enthesitis at the Single Enthesis Level
Andre Lucas Ribeiro¹, Sibel Aydin², Gurjit Kaeley³, Fahmeen Afgani⁴, Catherine Bakewell⁵, Marcos Rosemffet⁶, Minna Kohler⁷, Amir Haddad⁸, Maria S. Stoenoiu⁹, Ari Polachek¹⁰, josefina marin¹¹, Arnon Katz¹² and Lihi Eder¹³, ¹Women's College Hospital & University of Toronto, Porto Alegre, Rio Grande do Sul, Brazil, ²University of Ottawa - Ottawa, Ottawa, ON, Canada, ³UF COM-J, Ponte Vedra Beach, FL, ⁴Women's College Hospital, Toronto, Canada, ⁵Intermountain Healthcare, Salt Lake City, UT, ⁶Instituto de Rehabilitación Psicofísica, Capital Federal, Argentina, ⁷Massachusetts General Hospital, Boston, MA, ⁸Carmel Medical Centre, Haifa, Israel, ⁹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁰Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel, ¹¹Hospital Italiano de Buenos Aires, buenos aires, Argentina, ¹²GRAPPA - Patient Research Partner, Haifa, Israel, ¹³University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada
Background/Purpose: Clinical enthesitis occurs in 30-40% of psoriatic arthritis (PsA) patients, but its clinical diagnosis is challenging due to similarities to non-specific entheseal pain. Despite…
Abstract Number: 0075 • ACR Convergence 2024
Micro-RNAs as Biomarkers for Methotrexate Treatment Response in Patients with Psoriatic Arthritis
Darshini Ganatra¹, Omar Cruz Correa¹, Ameth Garrido², Starlee Lively³, Rohan Apurva Machhar⁴, Remy Pollock⁵, Mohit Kapoor⁶ and Dafna Gladman⁷, ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³UHN, Toronto, Canada, ⁴Novartis, Mississauga, ON, Canada, ⁵Pfizer, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis linked to psoriasis, a chronic skin and nail disease. PsA is a progressive joint disease…
Abstract Number: 0421 • ACR Convergence 2024
The Effect of Biologic Treatment for Psoriatic Arthritis and Axial Spondyloarthritis on Semen Parameters – a Longitudinal Study
Katya Meridor¹, Shimi Barda², sara Pel³, sharon Nevo², Julia Berman², daphna paran⁴, Ori Elkayam⁵ and Ari Polachek⁶, ¹Tel Aviv Medical Center, Kfar Saba, Israel, ²Tel-Aviv Medical Center, Tel-Aviv, Israel, ³Tel-Aviv Medical Center, Petah-Tikva, Israel, ⁴Tel-Aviv Medical Center, EVEN-YEHUDA, Israel, ⁵Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁶Tel-Aviv Medical Center, Tel-Aviv, Israel, Petah-Tikva, Israel
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) are commonly diagnosed in young males in their reproductive years. However, only a few studies have investigated…
Abstract Number: 0594 • ACR Convergence 2024
Real-world Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-week Multicenter Retrospective Review
Siddhartha Sood¹, Alexander Rimke², Brian Rankin³, Abrahim Abduelmula⁴, jorge Georgakopoulos⁴, Khalad Maliyar⁴, Ahmed Bagit⁵, Fernejoy Leung⁶, Alim Devani⁶, Ronald Vender⁷, Jensen Yeung⁴ and Vimal Prajapati³, ¹Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ²Dermatology Research Institute, Calgary, AB, Canada, ³Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada, ⁵Temerty Faculty of Medicine, University of Toronto, Toronto, Canada, ⁶Skin Health & Wellness Centre, Calgary, AB, Canada, ⁷Division of Dermatology, Department of Medicine, McMaster University, Hamilton, Canada
Background/Purpose: While biologic switching is common in routine clinical practice, limited information exists on switching within class from another IL-17i to bimekizumab. We conducted a…
Abstract Number: 1045 • ACR Convergence 2024
Impact of Stable Rheumatologic Therapy on Outcomes of Depression in Members with Rheumatoid Arthritis, Psoriatic Arthritis, and Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Rheumatic diseases, such as rheumatoid arthritis (RA), psoriatic arthritis (PA), and systemic lupus erythematosus (SLE) can significantly impact quality of life. This burden extends…

1
2
3
…
81
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.